IN 1992, HANSSON ET AL1 PROPOSED A NOVEL DESIGN, THE prospective randomized open trial with blinded end-point assessments. The lack of blinding of investigators and patients simplified the conduct of the trial, which would become more similar to routine medical practice than the blinded design. The use of blinding for the adjudication of outcomes would preserve the benefits of a fully blinded trial. A number of trials have used this design to evaluate antihypertensive agents and more recently antidiabetic agents.2"4 These trials were thought to produce valid and, perhaps, more generalizable results
展开▼
机译：1992年，HANSSON ET AL1提出了一种新颖的设计，即具有盲点评估的前瞻性随机开放试验。研究人员和患者没有盲目性，简化了试验的进行，与盲目设计相比，这将更类似于常规医学实践。使用盲法判断结果将保留完全盲法试验的益处。许多试验已经使用这种设计评估了降压药和最近的降糖药。2“ 4这些试验被认为可以产生有效的，也许是更普遍的结果
展开▼
